ALISO VIEJO, Calif., July 28, 2009 (GLOBE NEWSWIRE) -- Clarient, Inc. (Nasdaq:CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it will report its financial results for the second quarter ended June 30, 2009 after the stock market closes on Tuesday, August 4th.
Date: Tuesday, August 4, 2009 Start Time: 5:00 pm EDT Call-in Number: 1-877-941-6012 (U.S.) / 480-629-9771 (International) Conference ID Number: 4121615 Webcast: www.clarientinc.com/investor Web Replay: For those unable to participate in the live broadcast, a replay of the webcast will be archived at www.clarientinc.com/investor shortly after the call, and will be available for one year. Speakers: Ron Andrews, Vice Chairman and CEO; Michael Pellini, MD, President and COO; Raymond Land, CFO Format: Presentation of second quarter 2009 financial results followed by Q&A
About Clarient
Clarient combines innovative diagnostic technologies with world class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing advanced oncology testing and diagnostic services available both onsite and over the web. The Company is also developing new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. www.clarientinc.com